Market Access FDA approval numbers soar after COVID troubles The FDA released its overview of 2023 and the drugs it had approved during the year.
Events Partner Content 3rd Annual Complement-based Drug Development Summit 2019 November 13-15, 2019 | Boston, MA
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
